Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105


Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia.

Vollenberg R, Jouni R, Norris PAA, Burg-Roderfeld M, Cooper N, Rummel MJ, Bein G, Marini I, Bayat B, Burack R, Lazarus AH, Bakchoul T, Sachs UJ.

Haematologica. 2019 Jun;104(6):1237-1243. doi: 10.3324/haematol.2018.211086. Epub 2019 Mar 28.


Antiplatelet antibody-induced thrombocytopenia does not correlate with megakaryocyte abnormalities in murine immune thrombocytopenia.

Guo L, Kapur R, Aslam R, Hunt K, Hou Y, Zufferey A, Speck ER, Rondina MT, Lazarus AH, Ni H, Semple JW.

Scand J Immunol. 2018 Jul;88(1):e12678. doi: 10.1111/sji.12678.


GPIbα is required for platelet-mediated hepatic thrombopoietin generation.

Xu M, Li J, Neves MAD, Zhu G, Carrim N, Yu R, Gupta S, Marshall J, Rotstein O, Peng J, Hou M, Kunishima S, Ware J, Branch DR, Lazarus AH, Ruggeri ZM, Freedman J, Ni H.

Blood. 2018 Aug 9;132(6):622-634. doi: 10.1182/blood-2017-12-820779. Epub 2018 May 24.


Anti-RhD reduces levels of detectable RhD antigen following anti-RhD infusion.

Sullivan HC, Arthur CM, Thompson L, Patel SR, Stowell SR, Hendrickson JE, Lazarus AH.

Transfusion. 2018 Feb;58(2):542-544. doi: 10.1111/trf.14452. No abstract available.


Erythrocyte Saturation with IgG Is Required for Inducing Antibody-Mediated Immune Suppression and Impacts Both Erythrocyte Clearance and Antigen-Modulation Mechanisms.

Cruz-Leal Y, Marjoram D, Lazarus AH.

J Immunol. 2018 Feb 15;200(4):1295-1305. doi: 10.4049/jimmunol.1700874. Epub 2018 Jan 22.


Red blood cell antibody-induced anemia causes differential degrees of tissue hypoxia in kidney and brain.

Mistry N, Mazer CD, Sled JG, Lazarus AH, Cahill LS, Solish M, Zhou YQ, Romanova N, Hare AGM, Doctor A, Fisher JA, Brunt KR, Simpson JA, Hare GMT.

Am J Physiol Regul Integr Comp Physiol. 2018 Apr 1;314(4):R611-R622. doi: 10.1152/ajpregu.00182.2017. Epub 2018 Jan 10.


Immunoglobulin G Fc glycans are not essential for antibody-mediated immune suppression to murine erythrocytes.

Marjoram D, Cruz-Leal Y, Bernardo L, Le NPL, Crispin M, Yu X, Uchikawa M, Lazarus AH.

Blood. 2017 Dec 28;130(26):2902-2905. doi: 10.1182/blood-2017-06-793729. Epub 2017 Nov 6. No abstract available.


Prevention of hemolytic disease of the fetus and newborn: what have we learned from animal models?

Cruz-Leal Y, Marjoram D, Lazarus AH.

Curr Opin Hematol. 2017 Nov;24(6):536-543. doi: 10.1097/MOH.0000000000000374. Review.


Antibody-mediated immune suppression is improved when blends of anti-RBC monoclonal antibodies are used in mice.

Bernardo L, Amash A, Marjoram D, Lazarus AH.

Blood. 2016 Aug 25;128(8):1076-80. doi: 10.1182/blood-2016-01-692178. Epub 2016 Jun 21.


Mechanistic properties of intravenous immunoglobulin in murine immune thrombocytopenia: support for FcγRIIB falls by the wayside.

Crow AR, Lazarus AH.

Semin Hematol. 2016 Apr;53 Suppl 1:S20-2. doi: 10.1053/j.seminhematol.2016.04.007. Epub 2016 Apr 6.


CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fcγ Receptor- and Complement Receptor 3-Dependent Mechanisms.

Amash A, Wang L, Wang Y, Bhakta V, Fairn GD, Hou M, Peng J, Sheffield WP, Lazarus AH.

J Immunol. 2016 Apr 15;196(8):3331-40. doi: 10.4049/jimmunol.1502198. Epub 2016 Mar 4.


Targeting FcγRs to treat antibody-dependent autoimmunity.

Yu X, Lazarus AH.

Autoimmun Rev. 2016 Jun;15(6):510-2. doi: 10.1016/j.autrev.2016.02.006. Epub 2016 Feb 12. Review.


CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia.

Guo L, Kapur R, Aslam R, Speck ER, Zufferey A, Zhao Y, Kim M, Lazarus AH, Ni H, Semple JW.

Blood. 2016 Feb 11;127(6):735-8. doi: 10.1182/blood-2015-06-655126. Epub 2015 Nov 10.


Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity.

Yu X, Menard M, Prechl J, Bhakta V, Sheffield WP, Lazarus AH.

Blood. 2016 Jan 7;127(1):132-8. doi: 10.1182/blood-2015-08-664656. Epub 2015 Oct 23.


IgG-Mediated Immune Suppression to Erythrocytes by Polyclonal Antibodies Can Occur in the Absence of Activating or Inhibitory Fcγ Receptors in a Full Mouse Model.

Bernardo L, Yu H, Amash A, Zimring JC, Lazarus AH.

J Immunol. 2015 Sep 1;195(5):2224-30. doi: 10.4049/jimmunol.1500790. Epub 2015 Jul 17.


CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.

Ma L, Simpson E, Li J, Xuan M, Xu M, Baker L, Shi Y, Yougbaré I, Wang X, Zhu G, Chen P, Prud'homme GJ, Lazarus AH, Freedman J, Ni H.

Blood. 2015 Jul 9;126(2):247-56. doi: 10.1182/blood-2015-03-635417. Epub 2015 Jun 2.


A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects.

Yu X, Menard M, Seabright G, Crispin M, Lazarus AH.

Transfusion. 2015 Jun;55(6 Pt 2):1501-11. doi: 10.1111/trf.13032. Epub 2015 Mar 6.


RhD Specific Antibodies Are Not Detectable in HLA-DRB1(*)1501 Mice Challenged with Human RhD Positive Erythrocytes.

Bernardo L, Denomme GA, Shah K, Lazarus AH.

Adv Hematol. 2014;2014:470242. doi: 10.1155/2014/470242. Epub 2014 Dec 31.


CD44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcγRIIb genetic disruption.

Crow AR, Amash A, Lazarus AH.

Transfusion. 2015 Jun;55(6 Pt 2):1492-500. doi: 10.1111/trf.12957. Epub 2014 Dec 15.


Antibody-mediated immune suppression of erythrocyte alloimmunization can occur independently from red cell clearance or epitope masking in a murine model.

Yu H, Stowell SR, Bernardo L, Hendrickson JE, Zimring JC, Amash A, Uchikawa M, Lazarus AH.

J Immunol. 2014 Sep 15;193(6):2902-10. doi: 10.4049/jimmunol.1302287. Epub 2014 Aug 13.


Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.

Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, Maraskovsky E, Zuercher AW, Neschadim A, Leontyev D, McKenzie BS, Käsermann F.

J Immunol. 2014 Jun 1;192(11):5031-8. doi: 10.4049/jimmunol.1301611. Epub 2014 Apr 23.


Allogeneic platelet transfusions prevent murine T-cell-mediated immune thrombocytopenia.

Guo L, Yang L, Speck ER, Aslam R, Kim M, McKenzie CG, Lazarus AH, Ni H, Hou M, Freedman J, Semple JW.

Blood. 2014 Jan 16;123(3):422-7. doi: 10.1182/blood-2013-08-523308. Epub 2013 Nov 20.


Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway.

Crow AR, Yu H, Han D, Lazarus AH.

PLoS One. 2013 Aug 5;8(8):e71882. doi: 10.1371/journal.pone.0071882. Print 2013.


Monoclonal versus polyclonal anti-D in the treatment of ITP.

Lazarus AH.

Expert Opin Biol Ther. 2013 Oct;13(10):1353-6. doi: 10.1517/14712598.2013.825243. Epub 2013 Aug 7.


CD44 antibodies and immune thrombocytopenia in the amelioration of murine inflammatory arthritis.

Mott PJ, Lazarus AH.

PLoS One. 2013 Jun 13;8(6):e65805. doi: 10.1371/journal.pone.0065805. Print 2013.


Antibody specific for the glycophorin A complex mediates intravenous immune globulin-resistant anemia in a murine model.

Chen X, Ghaffar H, Jen CC, Lazarus AH.

Transfusion. 2014 Mar;54(3):655-64. doi: 10.1111/trf.12300. Epub 2013 Jun 19.


Innate and adaptive immunity in immune thrombocytopenia.

Lazarus AH, Semple JW, Cines DB.

Semin Hematol. 2013 Jan;50 Suppl 1:S68-70. doi: 10.1053/j.seminhematol.2013.03.012. Review.


Intravenous immunoglobulin prevents murine antibody-mediated acute lung injury at the level of neutrophil reactive oxygen species (ROS) production.

Semple JW, Kim M, Hou J, McVey M, Lee YJ, Tabuchi A, Kuebler WM, Chai ZW, Lazarus AH.

PLoS One. 2012;7(2):e31357. doi: 10.1371/journal.pone.0031357. Epub 2012 Feb 17.


The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia.

Crow AR, Suppa SJ, Chen X, Mott PJ, Lazarus AH.

Blood. 2011 Dec 8;118(24):6403-6. doi: 10.1182/blood-2011-08-374223. Epub 2011 Oct 14.


Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb.

Liang Y, Qiu H, Glinka Y, Lazarus AH, Ni H, Prud'homme GJ, Wang Q.

J Gene Med. 2011 Sep;13(9):470-7. doi: 10.1002/jgm.1598.


IVIg conducts DC-platelet nuptials.

Lazarus AH.

Blood. 2010 Dec 2;116(23):4740-1. doi: 10.1182/blood-2010-09-303420. No abstract available.


Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?

Crow AR, Song S, Suppa SJ, Ma S, Reilly MP, Andre P, McKenzie SE, Lazarus AH.

Blood. 2011 Jan 20;117(3):971-4. doi: 10.1182/blood-2010-05-280115. Epub 2010 Nov 2.


Transfusion of antibody-opsonized red blood cells results in a shift in the immune response from the red blood cell to the antibody in a murine model.

Brinc D, Le-Tien H, Crow AR, Semple JW, Freedman J, Lazarus AH.

Transfusion. 2010 Sep;50(9):2016-25. doi: 10.1111/j.1537-2995.2010.02645.x.


Adoptive-transfer effects of intravenous immunoglobulin in autoimmunity.

Lazarus AH.

J Clin Immunol. 2010 May;30 Suppl 1:S20-3. doi: 10.1007/s10875-010-9410-9. Review.


Mechanisms of platelet recovery in ITP associated with therapy.

Pang SJ, Lazarus AH.

Ann Hematol. 2010 Jul;89 Suppl 1:31-5. Epub 2010 Feb 24. Review.


Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn.

Brinc D, Lazarus AH.

Hematology Am Soc Hematol Educ Program. 2009:185-91. doi: 10.1182/asheducation-2009.1.185. Review.


A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy.

Chow L, Aslam R, Speck ER, Kim M, Cridland N, Webster ML, Chen P, Sahib K, Ni H, Lazarus AH, Garvey MB, Freedman J, Semple JW.

Blood. 2010 Feb 11;115(6):1247-53. doi: 10.1182/blood-2009-09-244772. Epub 2009 Dec 10.


Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders.

Imbach P, Lazarus AH, Kühne T.

Vox Sang. 2010 Apr;98(3 Pt 2):385-94. doi: 10.1111/j.1423-0410.2009.01264.x. Epub 2009 Oct 11. Review.


Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models?

Brinc D, Denomme GA, Lazarus AH.

Curr Opin Hematol. 2009 Nov;16(6):488-96. doi: 10.1097/MOH.0b013e32833199ed. Review.


New insight into the mechanism of action of IVIg: the role of dendritic cells.

Crow AR, Brinc D, Lazarus AH.

J Thromb Haemost. 2009 Jul;7 Suppl 1:245-8. doi: 10.1111/j.1538-7836.2009.03420.x. Review.


Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.

Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB.

Blood. 2009 Apr 2;113(14):3154-60. doi: 10.1182/blood-2008-07-166439. Epub 2008 Dec 18.


Transfusion of IgG-opsonized foreign red blood cells mediates reduction of antigen-specific B cell priming in a murine model.

Brinc D, Le-Tien H, Crow AR, Siragam V, Freedman J, Lazarus AH.

J Immunol. 2008 Jul 15;181(2):948-53.


A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?

Crow AR, Song S, Semple JW, Freedman J, Lazarus AH.

Blood. 2007 Jan 1;109(1):155-8. Epub 2006 Sep 5.


Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia.

Crow AR, Song S, Siragam V, Lazarus AH.

Pediatr Blood Cancer. 2006 Oct 15;47(5 Suppl):710-3. Review.


Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells.

Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH.

Nat Med. 2006 Jun;12(6):688-92. Epub 2006 May 21.


Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia.

Leytin V, Mykhaylov S, Starkey AF, Allen DJ, Lau H, Ni H, Semple JW, Lazarus AH, Freedman J.

Br J Haematol. 2006 Apr;133(1):78-82. Erratum in: Br J Haematol. 2006 May;133(4):452.


A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy.

Ni H, Chen P, Spring CM, Sayeh E, Semple JW, Lazarus AH, Hynes RO, Freedman J.

Blood. 2006 Apr 1;107(7):2976-83. Epub 2005 Nov 29.

Supplemental Content

Loading ...
Support Center